EVO Stock Price, Chart, Stats & News

EVO chart
Fundamentals
Gross margin | 10.82% |
Operating margin | -11.30% |
Pretax margin | -17.47% |
Net margin | -21.02% |
Effective tax rate | -20.35% |
ROA | -8.97% |
ROE | -17.05% |
D/E | 0.61x |
Interest coverage ratio | -5.66x |
EVO valuation
P/E | – |
P/S | 0.99x |
P/B | 0.93x |
P/CF | 528.58x |
P/FCF | -8.32x |
P/OCF | 528.58x |
PEG | 2.35x |
EV multiple | -4.91x |
About
Evotec SE operates globally as a dedicated partner, specializing in the discovery and advancement of new pharmaceutical products for the biotechnology and pharmaceutical sectors. Its comprehensive research and development initiatives encompass a broad spectrum of medical areas, such as metabolic disorders (including diabetes and its complications), fibrosis, infectious conditions, central nervous system (CNS) diseases, oncology, pain management, inflammatory ailments, immunological dysfunctions, rare diseases, respiratory conditions, and women's health. The company maintains strategic alliances and collaborations with numerous prominent organizations, including Bayer AG, Lilly, Chinook Therapeutics, Novo Nordisk A/S, Galapagos, Pfizer Inc., CONBA Pharmaceutical Co., Ltd., Bristol Myers Squibb Company, Zhejiang JingXin Pharmaceutical Co., Ltd, Kazia Therapeutics, Apeiron Biologics, and Takeda Pharmaceuticals.
Similar securities
Based on sector and market capitalization











